SAGA Diagnostics and AstraZeneca enter assay development agreement

SAGA Diagnostics, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, has entered into an assay development agreement with Astra Zeneca to develop SAGAsafe dPCR assays towards undisclosed methylated targets for analyses of tissue samples and liquid biopsies.  

James Hadfield, Director Epigenomics, Oncology Translational Medicine, Oncology R&D, AstraZeneca, said: “We have chosen to partner with SAGA because of the ultrasensitive performance of the SAGAsafe technology and possibility to custom tailor highly complex dPCR assays to meet our desired analytical standards. We are excited about exploring this new area together with SAGA.” 

SAGAsafe is an improvement of digital PCR that enables approximately 100-fold increased sensitivity compared to competitor methods, and can be used to quantify sequence variants in tissue samples as well as liquid biopsies such as blood plasma with unprecedented performance.   

Lao Saal, co-founder and COO of SAGA Diagnostics, said: “We are honoured that Dr. Hadfield and his team have selected SAGA and the SAGAsafe platform to develop ultrasensitive dPCR methylation assays for AstraZeneca’s clinical research study, and are pleased to be working together again.” 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free